These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 8970360

  • 1. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J.
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [Abstract] [Full Text] [Related]

  • 2. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N, Gabdrakhmanova L, Hammer M, Rosenberger C, Oppert M, Volk HD, Reinke P.
    Transpl Infect Dis; 2005 Dec; 7(3-4):133-6. PubMed ID: 16390402
    [Abstract] [Full Text] [Related]

  • 3. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, Weir MA, House AA.
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [Abstract] [Full Text] [Related]

  • 4. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM, Burkett P, Divo M, Keller S, Rosas IO, Trindade A, Mody GN, Singh SK, El-Chemaly S, Camp PC, Goldberg HJ, Mallidi HR.
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [Abstract] [Full Text] [Related]

  • 5. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S, Renner C, Hammer M, Abdul-Khaliq H, Lehmkuhl HB, Berger F, Hetzer R, Reinke P.
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [Abstract] [Full Text] [Related]

  • 6. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.
    Wheless SA, Gulley ML, Raab-Traub N, McNeillie P, Neuringer IP, Ford HJ, Aris RM.
    Am J Respir Crit Care Med; 2008 Nov 15; 178(10):1060-5. PubMed ID: 18755927
    [Abstract] [Full Text] [Related]

  • 7. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients.
    Shapiro NL, Tang CG, Bhattacharyya N.
    Laryngoscope; 2011 Aug 15; 121(8):1718-25. PubMed ID: 21792960
    [Abstract] [Full Text] [Related]

  • 8. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.
    Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR.
    J Heart Lung Transplant; 2002 May 15; 21(5):547-54. PubMed ID: 11983544
    [Abstract] [Full Text] [Related]

  • 9. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
    Muchtar E, Kramer MR, Vidal L, Ram R, Gurion R, Rosenblat Y, Bakal I, Shpilberg O.
    Transplantation; 2013 Oct 15; 96(7):657-63. PubMed ID: 23823652
    [Abstract] [Full Text] [Related]

  • 10. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A, Dierickx D, Verbeken EK, Tousseyn T, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verleden GM, Van Raemdonck DE, Vos R.
    Clin Transplant; 2017 Jul 15; 31(7):. PubMed ID: 28383790
    [Abstract] [Full Text] [Related]

  • 11. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD, Hsu DT, Kichuk MR, Garvin JH, Stolar CJ, Haddad J, Stylianos S, Michler RE, Chadburn A, Knowles DM, Addonizio LJ.
    J Heart Lung Transplant; 1998 Dec 15; 17(12):1161-6. PubMed ID: 9883755
    [Abstract] [Full Text] [Related]

  • 12. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML, Swinnen LJ, Plaisance KT, Schnell C, Grogan TM, Schneider BG, Southwest Oncology Group.
    Transplantation; 2003 Sep 27; 76(6):959-64. PubMed ID: 14508361
    [Abstract] [Full Text] [Related]

  • 13. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
    Verschuuren E, van der Bij W, de Boer W, Timens W, Middeldorp J, The TH.
    J Med Virol; 2003 Feb 27; 69(2):258-66. PubMed ID: 12683416
    [Abstract] [Full Text] [Related]

  • 14. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 27; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 15. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Nephrol Dial Transplant; 2012 Jul 27; 27(7):2971-9. PubMed ID: 22273720
    [Abstract] [Full Text] [Related]

  • 16. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL.
    Clin Transplant; 1995 Feb 27; 9(1):53-9. PubMed ID: 7742583
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W.
    Transplantation; 2007 Feb 27; 83(4):433-8. PubMed ID: 17318076
    [Abstract] [Full Text] [Related]

  • 18. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 27; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 19. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr 27; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

  • 20. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center.
    Angel LF, Cai TH, Sako EY, Levine SM.
    Ann Transplant; 2000 Apr 27; 5(3):26-30. PubMed ID: 11147026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.